Avery Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Avery Therapeutics's estimated annual revenue is currently $2.3M per year.(i)
  • Avery Therapeutics's estimated revenue per employee is $193,750

Employee Data

  • Avery Therapeutics has 12 Employees.(i)
  • Avery Therapeutics grew their employee count by 0% last year.

Avery Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M40%N/AN/A
#2
$0.9M50%N/AN/A
#3
$0.8M40%N/AN/A
#4
$5.3M340%N/AN/A
#5
$2.5M12-8%N/AN/A
#6
$1.1M60%N/AN/A
#7
$0.9M50%N/AN/A
#8
$2.2M2921%$58.2MN/A
#9
$171.9M1109-3%N/AN/A
#10
$0.9M50%N/AN/A
Add Company

What Is Avery Therapeutics?

Avery Therapeutics’ mission is to advance tissue-engineered therapeutics to treat diseases and injuries to human muscle. Avery’s first product, MyCardia™ is a tissue engineered graft for treatment of chronic heart failure. Chronic heart failure is a critical need worldwide with 26M people diagnosed and no therapies that effectively reverse the disease process or restore function to the heart long term. MyCardia™ has the potential to be the first available therapy that regenerates tissue and restores the heart to effective function for a high quality of life. MyCardia™ is a three part product comprised of a bio- absorbable scaffold seeded with fibroblasts and induced pluripotent stem cell derived cardiomyocytes. Each cell type provides a unique therapeutic element and taken together synergistically improves the heart. MyCardia™ mimics key molecular and cellular attributes of cardiac tissue and behaves like cardiac tissue. MyCardia™ beats spontaneously and synchronously and electrically couples with the heart. We have data showing that MyCardia™ improves cardiac function in pre-clinical models of heart failure and results in generation of new blood vessels and heart muscle. Of additional importance is that pre-clinical studies with MyCardia™ have shown improvements in diastolic function, which has the potential to be immensely impactful in the heart failure population since there are no existing therapies to treat diastolic dysfunction.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$2.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M129%N/A
#2
$1.8M120%N/A
#3
$2.5M12-8%N/A
#4
$0.9M120%N/A
#5
$2.3M12-8%N/A